Document is current
Any future updates will be listed below
-
Authors
Nichani, Prem A. H.
Popovic, Marko M. https://orcid.org/0000-0002-0370-5968
Dhoot, Arjan S. https://orcid.org/0000-0002-6608-2403
Pathak, Ananya
Muni, Rajeev H. https://orcid.org/0000-0003-0465-6472
Kertes, Peter J. https://orcid.org/0000-0002-0348-5096
- License Information
-
More Information
Article History
Received: 1 March 2022
Revised: 4 November 2022
Accepted: 1 February 2023
First Online: 1 March 2023
Competing interests
: PN, ASD, AP: None. MMP: Physicians’ Services Incorporated (PSI) Foundation (RI). RHM: Allergan (C), Bayer (C, RI), Novartis (C, RI), Roche (C). PJK: Alcon (C), Allergan (RI), ArcticDx (E), Bayer (C, RI, RP), Novartis (C, RI, RP), Novelty Nobility (C), Roche (RI). <i>Legend:</i> C – consultant/consulting fees; E – equity owner; S – speaker honoraria; RI – research grant/financial support (to institution); RP – research grant/financial support (personal)
: The paper is exempt from ethical committee approval given that it is a meta-analysis of previously published data as opposed to a primary study using direct/individual patient data. This research in its entirety complies with the guidelines for human studies and should include evidence that the research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.
